ENT-03: A Novel Compound for Obesity and Type 2 Diabetes

ENT-03 is a centrally-acting endogenous steroidal molecule (spermine-bile acid) that regulates whole-body responsiveness to insulin, energy homeostasis and body weight.

  • Potent inhibitor of PTP1, an established Obesity and Type 2 Diabetes target

  • Rapidly normalizes glucose and induces weight loss

  • Has additive effects with GLP-1 agonists

  • Subcutaneously administered

  • Preserves lean muscle loss and has sustained effect after therapy cessation

Over 36 million Americans now live with diabetes and the numbers continue to increase. ENT-03 can help.

Obesity is prevalent in almost 38% of US adults and type 2 diabetes (T2D) affects approximately 9% of US adults. Obesity reduces lifespan and increases the risk of cardiovascular disease, T2D, hypertension, obstructive sleep apnea and some cancers. The cost of healthcare, caregiving, and hospice care exceeds $290 billion annually in the US, expected to increase to $1.1 trillion by 2050.

In animal studies with ENT-03, we have observed a rapid increase in insulin sensitivity and normalization of blood glucose levels prior to any weight loss. The treated animals had reduced food intake and lost significant amounts of weight, which was maintained for several months after treatment. Consequently, if approved, ENT-03 could be used as a stand-alone drug, or in combination with GLP-1 agonists which increase pancreatic insulin secretion and suppress eating behavior including interest in calorie rich foods.